REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma. Participants will be consented before starting standard-of-care concurrent temozolomide and radiotherapy. After enrollment, participants will enter an observational lead-in phase while receiving standard-of-care therapy off study. Approximately 4 weeks after temozolomide, participants will receive one study-specific 2 Gy fraction of maintenance radiotherapy directed at the post-operative cavity and areas of prior enhancing disease. The study will evaluate the safety and feasibility of delivering maintenance radiotherapy. Blood samples will also be collected before and after maintenance radiotherapy to descriptively compare myeloid-derived suppressor cell frequency.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem glejak wielopostaciowy
- •Wiek 18 lat lub więcej
- •Zaplanowana standardowa operacja i chemioterapia z napromienianiem
- •Ogólny stan zdrowia na poziomie co najmniej 70 procent
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Prawidłowe wyniki badań krwi (liczba krwinek białych, płytek i hemoglobiny)
- •Gotowość do stosowania antykoncepcji (jeśli dotyczy)
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Wcześniejsze napromienianie mózgu
- •Zaangażowanie pnia mózgu w obszar objęty napromienianiem
- •Niemożliwość wykonania badania MRI lub CT
- •Poważne problemy zdrowotne utrudniające uczestnictwo w badaniu (infekcje, problemy z sercem, zaburzenia psychiatryczne)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Minnesota Radiation Oncology
Minneapolis, United States
Trial contact
Lindsey Sloan
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.